The Scientific Committee invites authors to submit their abstracts.

Starting 1 January 2018, the new MedTech Europe code prohibits the direct sponsorship of delegates by Industry. As a result, these companies will now channel their support through trusted partners such as the ESCVS Society or the PCO, Overcome, which will be responsible for awarding any industry sponsored grants. Please more information please click HERE




Anaesthesia for Cardiac Surgery (last year) OR for ECLS + VAD
Aortic valve stenosis TAVI and new sutureless prosthesis
Cardiac insufficiency and cardiac assist devices
Cardiac Transplantation and EVAR
Congenital Heart Disease
Epicardial and endovascular treatment of atrial fibrillation
Heart Failure
Infections of the sternum and anterior thoracic wall
Minimally Invasive Cardiac Surgery
Nursing in cardiology and cardiac surgery
Surgically repair or replacement in GUCH patients


Abdominal aortic aneurysm
Aortic dissection
Carotid disease
Deep vein insufficiency
Peripheral occlusive disease
Superficial vein insufficiency
Thoracic aorta
Vascular access
Vascular biology/research


Aortic dissection and surgical treatment both open and endovascular
ECMO and vascular complications


Abstracts should be submitted according to the following instructions:

Language: English

Words: Minimum number of words: 400 & Maximum number of words: 600 (including titles, authors and affiliations)

Title: Concise, small letters

Abstracts for original articles should be divided into the following sections:

a) Aim: description of the objective/aim of the research
b) Methods: description of the methods used
c) Results: results of the research
d) Conclusion: brief conclusion

Abstracts for for case reports should be divided into the following sections:

a) Background: a brief introduction of the case reported
b) Case report: description of the case report

The text and the title must be free from abbreviations. Only the standard abbreviations used in medicine are accepted, whereas the other acronyms should be written in extenso the first time they appear in the abstract. After that, the acronym can be used. Eg: Non small cell lung cancer (NSCLC)

Figures, tables and references are not accepted.


The names of the authors should be written in upper/lower cases in the following way:

  1. Full name with first letter in upper case (e.g. John)
  2. Surname with first letter in upper case (e.g. Smith)

Please enter the FIRST NAME in full, followed by the LAST NAME, for each author without abbreviations (e.g. John Smith , and NOT J. Smith).


Affiliation details of all authors should be provided. Details should be written in the following order (when available) and the street address is not needed.

  1. Unit or Section
  2. Department
  3. University and/or Hospital
  4. Town
  5. Country

In case of multiple affiliations, please superscribe the relevant numbers
Please put a comma and a space between the names of the authors and  a semicolon between the authors’ affiliations

Example of authors’ affiliations:
In vivo tracking for cell therapies
M. Thompson 1, D. Wall 2, R.J. Hicks 1,3 , H.M. Prince2,3
1Department of Diagnostic Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia;
2Centre for Blood Cell Therapies, Peter MacCallum Cancer Centre, Melbourne, Australia;
3University of Melbourne, Melbourne, Australia